Polyphor successfully completes Wellcome Trust collaboration for development of novel antibiotics against multi-drug resistant Gram-negative pathogens
EQS Group-News: Polyphor AG / Key word(s): Financing/Financing
Allschwil, Switzerland, April 13th, 2018
The final milestone was the selection of a pre-clinical candidate series meeting a set of pre-defined criteria and was achieved ahead of schedule. Reaching the milestone led to the pay-ment of the final tranche of CHF 0.97M of the aggregate loan amount of CHF 2.3M under the convertible loan (Seeding Drug Discovery Award) first announced in February 2017.
The novel antibiotics target the most important Gram-negative ESKAPE* pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp) which are the leading cause of severe and often deadly infections throughout the world, such as bloodstream infections and pneumonia. Importantly, this new class of antibiotics is active both in vitro and in vivo against strains which have become resistant to most - and in some cases all - commonly used antibiotics including the "last resort" antibiotic colistin.
"Our OMPTAs are potentially the first new class of antibiotics against Gram-negative bacteria in 50 years," said Daniel Obrecht, CSO and co-founder of Polyphor.
"The first product of this class, the Pseudomonas selective drug murepavadin, is now in a global Phase III program. The support of the Wellcome Trust has been very important for us, accelerating the development of the next generation of OMPTA compounds. We believe their novel mechanism of action, targeting the outer membrane proteins of Gram-negative bacteria, provides for the potential to develop highly effective antibiotics against which pathogens may only slowly build resistance."
For further information please contact:
Polyphor is a clinical stage, privately held Swiss specialty pharma company which has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria in the last 50 years. The company's lead product, murepavadin, (POL7080) is in Phase III development against Pseudo-monas aeruginosa - recognized as a critical priority 1 pathogen by WHO. Polyphor is also deve-loping an immuno-oncology candidate, balixafortide (POL6326), which has achieved clinical proof of concept in a Phase Ib/proof of concept study in combination with eribulin in patients with ad-vanced breast cancer, and a pipeline of further preclinical antibiotics based on its OMPTA platform. Polyphor is based in Allschwil near Basel. For more information, please visit www.polyphor.com.
Document: Polyphor successfully completes Wellcome Trust collaboration for development of novel antibiotics against multi-drug resistant Gram-negative pathogens